Researchers at the University of Pennsylvania reported early results from the REDUCE trial, a study that examined whether the low‑cost medication spironolactone can improve blood‑pressure control in people who have survived a stroke. The findings were shared at the American Heart Association’s Scientific Sessions in Chicago, Nov. 6‑9, 2026.
Study design and participants
The trial enrolled 160 adults who were still experiencing elevated blood pressure despite standard post‑stroke care. Participants were randomly assigned to one of two groups: one group added spironolactone to their existing regimen, while the other continued with usual care alone. Researchers asked participants to record their home blood‑pressure readings over a six‑month period.
Key results
After three months, the average top (systolic) blood‑pressure reading was nearly eight points lower in the spironolactone group compared with the usual‑care group—about 126 mm Hg versus 133 mm Hg. In addition, 52 % of those taking spironolactone reached the recommended target of less than 130/80, versus only 30 % of patients receiving standard care.
“Lowering blood pressure is the most important step in preventing another stroke, yet many survivors struggle to reach recommended targets,” said study co‑lead author Dr. Jordana Cohen, an associate professor of medicine and epidemiology at the University of Pennsylvania.
Expert commentary
Dr. Alfred Joshua, a board‑certified emergency physician in California who was not involved in the trial, called the results encouraging but cautioned that the study did not prove spironolactone prevents future strokes. “We already know that controlling blood pressure lowers the risk of another stroke,” he told Fox News Digital. “This study measured blood pressure, so whether adding spironolactone leads to fewer repeat strokes is still an open question.”
Safety considerations
Spironolactone works by helping the body eliminate excess salt and water, which can lower blood pressure. It also raises potassium levels, so patients need regular monitoring to avoid hyper‑kalemia, especially those with kidney disease or who take other potassium‑raising medications. Dr. Joshua warned that high potassium can develop without symptoms and that the medication may cause dizziness if blood pressure falls too low.
“If your blood pressure remains high after a stroke, bring your home readings to your clinician and ask whether this medication is a good fit,” he advised.
Study limitations
The trial ended early with 160 participants instead of the planned 200, and about 15 % of participants lacked blood‑pressure data at the three‑month mark. Those taking spironolactone were also on slightly more antihypertensive drugs overall than the usual‑care group. The researchers emphasized that larger, longer‑term studies are needed to determine whether spironolactone can actually reduce the incidence of repeat strokes or heart attacks.
What this means for patients
For stroke survivors struggling to meet blood‑pressure goals, spironolactone may represent a low‑cost option to help achieve better control. However, patients should discuss the potential benefits and risks with their healthcare provider, especially regarding potassium monitoring and possible side effects.
Original reporting: Fox News (HLL/CB) — read the source article.